APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rivaroxaban

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

Selected research

Market Outlook & Growth Opportunities

Global Rivaroxaban Market Outlook and Growth Opportunities 2026

1 January 2026197 pages

Choose your research edition.

Industry ResearchRivaroxaban Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Rivaroxaban Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Rivaroxaban Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rivaroxaban Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Rivaroxaban Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.

This report provides an overview of the global Rivaroxaban market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Rivaroxaban and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rivaroxaban sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rivaroxaban market size, projected growth trends, production technologies, key applications, and end-use industries.

Rivaroxaban Segment by Company

Bayer

J&J

Rivaroxaban Segment by Type

2.5 mg

10 mg

15 mg

20 mg

Rivaroxaban Segment by Application

Acute Coronary Syndrome (ACS)

Venous Thromboembolism (VTE)

Rivaroxaban Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Rivaroxaban status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Rivaroxaban market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rivaroxaban significant trends, drivers, influence factors in global and regions.

6. To analyze Rivaroxaban competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rivaroxaban market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rivaroxaban and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rivaroxaban.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rivaroxaban market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rivaroxaban industry.

Chapter 3: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Rivaroxaban in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rivaroxaban Industry Trends Table 2. Rivaroxaban Industry Drivers Table 3. Rivaroxaban Industry Opportunities and Challenges Table 4. Rivaroxaban Industry Restraints Table 5. Global Rivaroxaban Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rivaroxaban Revenue Share by Company (2021-2026) Table 7. Global Rivaroxaban Sales Volume by Company (M Units) & (2021-2026) Table 8. Global Rivaroxaban Sales Volume Share by Company (2021-2026) Table 9. Global Rivaroxaban Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Rivaroxaban Company Ranking, (2024-2026) & (USD Million) Table 11. Global Rivaroxaban Key Company Manufacturing Base & Headquarters Table 12. Global Rivaroxaban Company, Product Type & Application Table 13. Global Rivaroxaban Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Rivaroxaban by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 2.5 mg Table 18. Significant Companies of 10 mg Table 19. Significant Companies of 15 mg Table 20. Significant Companies of 20 mg Table 21. Global Rivaroxaban Sales Volume by Type 2021 VS 2025 VS 2032 (M Units) Table 22. Global Rivaroxaban Sales Volume by Type (2021-2026) & (M Units) Table 23. Global Rivaroxaban Sales Volume by Type (2027-2032) & (M Units) Table 24. Global Rivaroxaban Sales Volume Share by Type (2021-2026) Table 25. Global Rivaroxaban Sales Volume Share by Type (2027-2032) Table 26. Global Rivaroxaban Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Rivaroxaban Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Rivaroxaban Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Rivaroxaban Sales Value Share by Type (2021-2026) Table 30. Global Rivaroxaban Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Acute Coronary Syndrome (ACS) Table 32. Significant Companies of Venous Thromboembolism (VTE) Table 33. Global Rivaroxaban Sales Volume by Application 2021 VS 2025 VS 2032 (M Units) Table 34. Global Rivaroxaban Sales Volume by Application (2021-2026) & (M Units) Table 35. Global Rivaroxaban Sales Volume by Application (2027-2032) & (M Units) Table 36. Global Rivaroxaban Sales Volume Share by Application (2021-2026) Table 37. Global Rivaroxaban Sales Volume Share by Application (2027-2032) Table 38. Global Rivaroxaban Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Rivaroxaban Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Rivaroxaban Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Rivaroxaban Sales Value Share by Application (2021-2026) Table 42. Global Rivaroxaban Sales Value Share by Application (2027-2032) Table 43. Global Rivaroxaban Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 44. Global Rivaroxaban Sales by Region (2021-2026) & (M Units) Table 45. Global Rivaroxaban Sales Market Share by Region (2021-2026) Table 46. Global Rivaroxaban Sales by Region (2027-2032) & (M Units) Table 47. Global Rivaroxaban Sales Market Share by Region (2027-2032) Table 48. Global Rivaroxaban Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Rivaroxaban Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Rivaroxaban Sales Value Share by Region (2021-2026) Table 51. Global Rivaroxaban Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Rivaroxaban Sales Value Share by Region (2027-2032) Table 53. Global Rivaroxaban Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Rivaroxaban Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Rivaroxaban Sales by Country: 2021 VS 2025 VS 2032 (M Units) Table 56. Global Rivaroxaban Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Rivaroxaban Sales by Country (2021-2026) & (M Units) Table 58. Global Rivaroxaban Sales Market Share by Country (2021-2026) Table 59. Global Rivaroxaban Sales by Country (2027-2032) & (M Units) Table 60. Global Rivaroxaban Sales Market Share by Country (2027-2032) Table 61. Global Rivaroxaban Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Rivaroxaban Sales Value Market Share by Country (2021-2026) Table 63. Global Rivaroxaban Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Rivaroxaban Sales Value Market Share by Country (2027-2032) Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Rivaroxaban Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Bayer Rivaroxaban Product Portfolio Table 69. Bayer Recent Development Table 70. J&J Company Information Table 71. J&J Business Overview Table 72. J&J Rivaroxaban Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. J&J Rivaroxaban Product Portfolio Table 74. J&J Recent Development Table 75. Key Raw Materials Table 76. Raw Materials Key Suppliers Table 77. Rivaroxaban Distributors List Table 78. Rivaroxaban Customers List Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Rivaroxaban Product Image Figure 2. Global Rivaroxaban Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rivaroxaban Sales Value (2021-2032) & (US$ Million) Figure 4. Global Rivaroxaban Sales (2021-2032) & (M Units) Figure 5. Global Rivaroxaban Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Rivaroxaban Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 2.5 mg Image Figure 10. 10 mg Image Figure 11. 15 mg Image Figure 12. 20 mg Image Figure 13. Global Rivaroxaban Sales Volume by Type (2021 VS 2025 VS 2032) & (M Units) Figure 14. Global Rivaroxaban Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Rivaroxaban Sales Volume Share by Type (2021-2032) Figure 16. Global Rivaroxaban Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Rivaroxaban Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Rivaroxaban Sales Value Share by Type (2021-2032) Figure 19. Acute Coronary Syndrome (ACS) Image Figure 20. Venous Thromboembolism (VTE) Image Figure 21. Global Rivaroxaban Sales Volume by Application (2021 VS 2025 VS 2032) & (M Units) Figure 22. Global Rivaroxaban Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Rivaroxaban Sales Volume Share by Application (2021-2032) Figure 24. Global Rivaroxaban Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Rivaroxaban Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Rivaroxaban Sales Value Share by Application (2021-2032) Figure 27. Global Rivaroxaban Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 28. Global Rivaroxaban Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Rivaroxaban Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Rivaroxaban Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Rivaroxaban Sales Value (2021-2032) & (US$ Million) Figure 32. North America Rivaroxaban Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Rivaroxaban Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Rivaroxaban Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Rivaroxaban Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Rivaroxaban Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Rivaroxaban Sales Value (2021-2032) & (US$ Million) Figure 38. South America Rivaroxaban Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Rivaroxaban Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Rivaroxaban Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Rivaroxaban Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Rivaroxaban Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Rivaroxaban Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Rivaroxaban Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Rivaroxaban Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 2.5 mg
  • 10 mg
  • 15 mg
  • 20 mg
Applications
  • Acute Coronary Syndrome (ACS)
  • Venous Thromboembolism (VTE)
Companies covered
  • Bayer
  • J&J

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Rivaroxaban Sales Value (2021-2032)
  4. 1.2.2 Global Rivaroxaban Sales Volume (2021-2032)
  5. 1.2.3 Global Rivaroxaban Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Rivaroxaban Market Dynamics
  1. 2.1 Rivaroxaban Industry Trends
  2. 2.2 Rivaroxaban Industry Drivers
  3. 2.3 Rivaroxaban Industry Opportunities and Challenges
  4. 2.4 Rivaroxaban Industry Restraints
3 Rivaroxaban Market by Company
  1. 3.1 Global Rivaroxaban Company Revenue Ranking in 2025
  2. 3.2 Global Rivaroxaban Revenue by Company (2021-2026)
  3. 3.3 Global Rivaroxaban Sales Volume by Company (2021-2026)
  4. 3.4 Global Rivaroxaban Average Price by Company (2021-2026)
  5. 3.5 Global Rivaroxaban Company Ranking (2024-2026)
  6. 3.6 Global Rivaroxaban Company Manufacturing Base and Headquarters
  7. 3.7 Global Rivaroxaban Company Product Type and Application
  8. 3.8 Global Rivaroxaban Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Rivaroxaban Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Rivaroxaban Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Rivaroxaban Market by Type
  1. 4.1 Rivaroxaban Type Introduction
  2. 4.1.1 2.5 mg
  3. 4.1.2 10 mg
  4. 4.1.3 15 mg
  5. 4.1.4 20 mg
  6. 4.2 Global Rivaroxaban Sales Volume by Type
  7. 4.2.1 Global Rivaroxaban Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Rivaroxaban Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Rivaroxaban Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Rivaroxaban Sales Value by Type
  11. 4.3.1 Global Rivaroxaban Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Rivaroxaban Sales Value by Type (2021-2032)
  13. 4.3.3 Global Rivaroxaban Sales Value Share by Type (2021-2032)
5 Rivaroxaban Market by Application
  1. 5.1 Rivaroxaban Application Introduction
  2. 5.1.1 Acute Coronary Syndrome (ACS)
  3. 5.1.2 Venous Thromboembolism (VTE)
  4. 5.2 Global Rivaroxaban Sales Volume by Application
  5. 5.2.1 Global Rivaroxaban Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Rivaroxaban Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Rivaroxaban Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Rivaroxaban Sales Value by Application
  9. 5.3.1 Global Rivaroxaban Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Rivaroxaban Sales Value by Application (2021-2032)
  11. 5.3.3 Global Rivaroxaban Sales Value Share by Application (2021-2032)
6 Rivaroxaban Regional Sales and Value Analysis
  1. 6.1 Global Rivaroxaban Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rivaroxaban Sales by Region (2021-2032)
  3. 6.2.1 Global Rivaroxaban Sales by Region: 2021-2026
  4. 6.2.2 Global Rivaroxaban Sales by Region (2027-2032)
  5. 6.3 Global Rivaroxaban Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Rivaroxaban Sales Value by Region (2021-2032)
  7. 6.4.1 Global Rivaroxaban Sales Value by Region: 2021-2026
  8. 6.4.2 Global Rivaroxaban Sales Value by Region (2027-2032)
  9. 6.5 Global Rivaroxaban Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Rivaroxaban Sales Value (2021-2032)
  12. 6.6.2 North America Rivaroxaban Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Rivaroxaban Sales Value (2021-2032)
  15. 6.7.2 Europe Rivaroxaban Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Rivaroxaban Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Rivaroxaban Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Rivaroxaban Sales Value (2021-2032)
  21. 6.9.2 South America Rivaroxaban Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Rivaroxaban Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Rivaroxaban Sales Value Share by Country, 2025 VS 2032
7 Rivaroxaban Country-level Sales and Value Analysis
  1. 7.1 Global Rivaroxaban Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rivaroxaban Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Rivaroxaban Sales by Country (2021-2032)
  4. 7.3.1 Global Rivaroxaban Sales by Country (2021-2026)
  5. 7.3.2 Global Rivaroxaban Sales by Country (2027-2032)
  6. 7.4 Global Rivaroxaban Sales Value by Country (2021-2032)
  7. 7.4.1 Global Rivaroxaban Sales Value by Country (2021-2026)
  8. 7.4.2 Global Rivaroxaban Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Rivaroxaban Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Rivaroxaban Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Rivaroxaban Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Rivaroxaban Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Rivaroxaban Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Rivaroxaban Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Rivaroxaban Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Rivaroxaban Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Rivaroxaban Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Rivaroxaban Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Rivaroxaban Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Rivaroxaban Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Rivaroxaban Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Rivaroxaban Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Rivaroxaban Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Rivaroxaban Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Rivaroxaban Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Rivaroxaban Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Rivaroxaban Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Rivaroxaban Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Rivaroxaban Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Rivaroxaban Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Rivaroxaban Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Rivaroxaban Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Rivaroxaban Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Rivaroxaban Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Rivaroxaban Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Rivaroxaban Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Rivaroxaban Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Rivaroxaban Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Rivaroxaban Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer
  2. 8.1.1 Bayer Company Information
  3. 8.1.2 Bayer Business Overview
  4. 8.1.3 Bayer Rivaroxaban Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Rivaroxaban Product Portfolio
  6. 8.1.5 Bayer Recent Developments
  7. 8.2 J&J
  8. 8.2.1 J&J Company Information
  9. 8.2.2 J&J Business Overview
  10. 8.2.3 J&J Rivaroxaban Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 J&J Rivaroxaban Product Portfolio
  12. 8.2.5 J&J Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rivaroxaban Value Chain Analysis
  2. 9.1.1 Rivaroxaban Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rivaroxaban Sales Mode & Process
  6. 9.2 Rivaroxaban Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rivaroxaban Distributors
  9. 9.2.3 Rivaroxaban Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst